Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOrthopedics/MusculoskeletalHealth New England Chondrocyte Prior Auth | OpenPa…
    Ask Trek AI about this page
    CurrentHealth-New-EnglandPolicy UM256POL

    Autologous Chondrocyte Implantation or Transplantation - Medical Policy

    Customize your policy alerts

    Sign up for Health-New-England Policy UM256POL alerts

    Get alerted when Policy UM256POL changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-necessity review for autologous chondrocyte implantation or transplantation across Commercial, Medicare Advantage, and Medicaid (BeHealthy) lines of business. Approval applies to knee procedures meeting applicable InterQual criteria; other joints or indications are considered experimental and investigational.

    Policy Summary
    PayerHealth-New-England
    PolicyAutologous Chondrocyte Implantation or Transplantation
    Policy CodePolicy UM256POL
    Change TypeNo material change
    Effective DateJune 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for CPT 27412 and HCPCS J7330 and S2112.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Applicable lines of business
    KneeApproval criteria site

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2016
    FDA approval year for MACI
    0–4Outerbridge scale
    YesPrior authorization required

    Coverage Criteria

    Knee autologous chondrocyte implantation

    For all lines of business, approval requires the applicable InterQual criteria:

    Applicable knee ACI approval criteria: The request must meet InterQual CP: Procedures, Arthroscopy or Arthroscopically Assisted Surgery, Knee criteria.

    The detailed InterQual criteria are not reproduced in this policy. Obtain the InterQual SmartSheet through the Health New England provider portal or by calling (413) 787-4004.

    Other joints or indications

    The following services are not covered under the policy’s approved indication:

    Experimental and investigational services: Autologous chondrocyte implantation for any joint other than the knee, including the talar joint, or for any indication other than those addressed by the applicable knee criteria is considered experimental and investigational.

    Autologous chondrocyte implantation involving any joint other than the knee, including the talar joint, is considered experimental and investigational and is not covered under the approved indication.

    Autologous chondrocyte implantation for indications other than those addressed by the applicable InterQual knee criteria is considered experimental and investigational and is not covered under the approved indication.

    Coding and Billing

    CPT CodesCPT
    27412Autologous chondrocyte implantation, knee.
    HCPC CodesHCPCS
    J7330Autologous cultured chondrocytes, implant.
    S2112Arthroscopy, knee, surgical, for harvesting of cartilage.

    Provider Actions and Authorization Requirements

    Prior Authorization

    Obtain prior authorization

    Prior authorization is required before services billed under CPT 27412 or HCPCS J7330 and S2112 are performed.

    • CPT 27412 — Autologous chondrocyte implantation, knee.
    • HCPCS J7330 — Autologous cultured chondrocytes, implant.
    • HCPCS S2112 — Arthroscopy, knee, surgical, for harvesting of cartilage.
    Prior Authorization

    Meet knee InterQual criteria

    For all lines of business, approval of autologous chondrocyte implantation requires the applicable InterQual criteria: CP: Procedures, Arthroscopy or Arthroscopically Assisted Surgery, Knee.

    • Obtain the InterQual SmartSheet through the Health New England provider portal or by calling (413) 787-4004.
    • Apply the criteria to requests for all lines of business.

    Background

    Autologous chondrocyte implantation resurfaces an articular cartilage defect by harvesting the patient's own healthy chondrocytes, expanding them in vitro, and implanting the expanded cells into the defect. Articular cartilage damage may cause pain, loss of function, disability, and eventual osteoarthritis. MACI is a matrix-induced form in which autologous chondrocytes are cultured on a bioresorbable porcine-derived collagen membrane before implantation into the damaged area.

    Definitions and Classification

    Autologous
    TermAutologous
    SourceCells or tissues from the same individual
    Recipient relationshipThe cells or tissues are obtained from the individual who will receive them
    Autologous Chondrocyte Transplant (ACT)
    ProcedureA two-step procedure to treat full-thickness articular cartilage defects down to the bone in the knee
    Step 1: Harvest and expansionThe patient's own healthy chondrocytes or cartilage cells are harvested and grown in the laboratory to generate more cells
    Step 2: Implantation
    Policy Summary
    PayerHealth-New-England
    PolicyAutologous Chondrocyte Implantation or Transplantation
    Policy CodePolicy UM256POL
    Change TypeNo material change
    Effective DateJune 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for CPT 27412 and HCPCS J7330 and S2112.
    SourceLink
    On This Page
    Coverage CriteriaCoding and BillingProvider Actions and Authorization RequirementsBackgroundDefinitions and Classification
    Documentation Required

    Submit clinical evidence

    When requesting prior authorization, the treating physician or primary care provider must submit clinical evidence showing that the patient meets the criteria for the treatment, testing, or surgical procedure.

    • Submit the clinical evidence and other supporting information with the prior authorization request.
    Denial Risk

    Verify the joint and indication

    Autologous chondrocyte implantation for joints other than the knee, including the talar joint, or for indications other than those addressed by the applicable knee InterQual criteria is considered experimental and investigational.

    • Confirm that the requested treatment is for the knee.
    • Confirm that the indication is addressed by the applicable knee InterQual criteria.
    Denial Risk

    Avoid incomplete documentation

    Prior authorization review cannot be completed when the treating physician or primary care provider does not submit clinical evidence and other information showing that the patient meets the applicable criteria.

    • Provide the required documentation and clinical information with the request.
    • Without this information, Health New England will not be able to properly review the request for prior authorization.
    The expanded chondrocytes are sent back to the surgeon for implantation
    MACI (Matrix-Induced Autologous Chondrocyte Implantation)
    Cell sourceAutologous cultured chondrocytes, meaning the patient's own cells
    MatrixThe expanded cells are placed on a porcine collagen membrane
    Implantation methodThe membrane is implanted into the area of cartilage damage and is then absorbed back into the patient's tissue
    Outerbridge Classification System
    Assessment methodA direct-visualization grading system based on arthroscopic or open examination of the joint
    PurposeA simple, easy-to-use, and reproducible system for grading articular cartilage lesions
    Grade rangeGrade 0 indicates no cartilage damage and Grade 4 indicates the most severe cartilage damage
    Outerbridge Grade 0
    ClassificationOuterbridge Grade 0 (0)
    Cartilage findingNormal cartilage
    Scale positionGrade 0, the level representing no cartilage damage
    Outerbridge Grade 1
    ClassificationOuterbridge Grade 1 (I)
    Cartilage findingArticular cartilage has softening and swelling
    Damage levelGrade 1 on the Outerbridge cartilage-damage scale
    Outerbridge Grade 2
    ClassificationOuterbridge Grade 2 (II)
    DefectArticular cartilage has a partial-thickness defect
    Surface and size limitSurface fissures do not reach subchondral bone or exceed 1.5 cm in diameter
    Outerbridge Grade 3
    ClassificationOuterbridge Grade 3 (III)
    Cartilage findingArticular cartilage has fissuring to the level of subchondral bone
    Diameter thresholdThe affected area has a diameter more than 1.5 cm
    Outerbridge Grade 4
    ClassificationOuterbridge Grade 4 (IV)
    Cartilage findingArticular cartilage is worn to the extent that subchondral bone is exposed
    Severity levelGrade 4, the most severe level on the Outerbridge cartilage-damage scale